Semaglutide vs Tirzepatide
A side-by-side comparison of the two most widely used GLP-1 receptor agonists — how they differ in mechanism, weight loss data, and side effect profiles.
Both semaglutide and tirzepatide are prescription medications. This comparison is for educational purposes only. Consult a healthcare professional for medical advice.
What Is Semaglutide?
Semaglutide is a GLP-1 receptor agonist — it exclusively targets the GLP-1 receptor to suppress appetite, slow gastric emptying, and enhance glucose-dependent insulin secretion. It was FDA-approved for type 2 diabetes in 2017 and for chronic weight management in 2021. The STEP clinical trial program demonstrated average weight loss of 14.9% of body weight over 68 weeks at the 2.4mg weekly dose. Semaglutide is administered as a once-weekly subcutaneous injection, with an oral formulation also available for diabetes management. Its 7-day half-life is achieved through an albumin-binding fatty acid side chain that resists DPP-4 degradation.
What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism provides additive metabolic benefits: GIP receptor activation enhances insulin sensitivity, may improve fat metabolism, and appears to moderate some of the gastrointestinal effects of pure GLP-1 agonism. FDA-approved for type 2 diabetes in 2022 and weight management in 2023, tirzepatide demonstrated average weight loss of up to 22.5% of body weight in the SURMOUNT-1 trial at the 15mg weekly dose — a result that exceeded all previous GLP-1 agonist trials.
How They Differ Mechanistically
The core difference is receptor selectivity. Semaglutide activates GLP-1 receptors only, while tirzepatide activates both GLP-1 and GIP receptors. GIP is the other major incretin hormone — like GLP-1, it is released from the gut in response to food and stimulates insulin secretion. But GIP also has distinct effects on fat tissue and may enhance lipid metabolism through pathways that GLP-1 alone does not access. The synergistic activation of both incretin pathways is believed to explain tirzepatide’s superior weight loss results. Research also suggests the GIP component may partially counteract the nausea caused by delayed gastric emptying, potentially improving tolerability at high efficacy doses.
Weight Loss Comparison
Head-to-head data from the SURPASS trials shows tirzepatide producing greater weight loss at all dose levels compared to semaglutide 1mg. The SURMOUNT-1 trial (tirzepatide vs placebo) showed 22.5% average weight loss at 15mg, while the STEP 1 trial (semaglutide vs placebo) showed 14.9% at 2.4mg. However, individual variability is significant — some patients respond better to one compound than the other, and factors like baseline BMI, metabolic health, diet, and physical activity all influence outcomes.
Side Effect Profile Comparison
Both compounds share similar gastrointestinal side effects: nausea (reported in 40–50% of users during titration), vomiting (15–25%), diarrhea (15–30%), and constipation (10–15%). Most side effects are transient and resolve within weeks. Both carry the same boxed warning for medullary thyroid carcinoma risk and contraindication with pancreatitis history. Some clinical data suggests tirzepatide may produce slightly less nausea at equally effective doses, potentially due to the GIP receptor’s moderating effect on gastric motility.
Side-by-Side Comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Mechanism | GLP-1 agonist only | Dual GIP/GLP-1 agonist |
| Max Weight Loss (trials) | Up to 14.9% | Up to 22.5% |
| Administration | Subcutaneous (weekly) | Subcutaneous (weekly) |
| Starting Dose | 0.25mg weekly | 2.5mg weekly |
| Max Dose | 2.4mg weekly | 15mg weekly |
| FDA Approved | Yes (2017/2021) | Yes (2022/2023) |
| Oral Option | Yes (for diabetes) | No |
| Key Trials | STEP program | SURMOUNT / SURPASS |
Related Reading
- Semaglutide vs Retatrutide — single vs triple receptor agonist comparison
- Tirzepatide vs Retatrutide — dual vs triple agonist comparison
- GLP-1 Side Effects — complete side effect guide for GLP-1 peptides
- GLP-1 Dosing Guide — titration schedules and dosing protocols
Frequently Asked Questions
Which is more effective for weight loss — semaglutide or tirzepatide?
Clinical trials show tirzepatide produces greater average weight loss (up to 22.5% body weight) compared to semaglutide (up to 14.9%). However, individual responses vary and both compounds produce clinically significant results.
Do semaglutide and tirzepatide have the same side effects?
Both share similar gastrointestinal side effects including nausea, vomiting, and diarrhea. Some studies suggest tirzepatide may have slightly lower nausea rates at equivalent efficacy doses due to the GIP component.
Can you switch from semaglutide to tirzepatide?
Switching should only be done under medical supervision. A healthcare provider will typically recommend a washout period and start the new compound at a low dose with standard titration.
Further Reading & Research
Explore independent research databases and regulatory resources.
Medical Disclaimer: GLP-1 receptor agonists including semaglutide and tirzepatide are prescription medications in most countries. The information on this page is for educational and research purposes only and does not constitute medical advice. Do not use prescription medications without a valid prescription from a licensed healthcare provider.